Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said, sending shares of the vaccine maker up 60% in premarket trading.
Show more
Register and share your invite link to earn from video plays and referrals.
